Suppression of CTC1 inhibits hepatocellular carcinoma cell growth and enhances RHPS4 cytotoxicity.
CTC1
G-quadruplex DNA
Hepatocellular carcinoma HCC
Liver cancer
RHSP4
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
13 Jul 2024
13 Jul 2024
Historique:
received:
12
03
2024
accepted:
25
06
2024
medline:
14
7
2024
pubmed:
14
7
2024
entrez:
13
7
2024
Statut:
epublish
Résumé
Although DNA repair mechanisms function to maintain genomic integrity, in cancer cells these mechanisms may negatively affect treatment efficiency. The strategy of targeting cancer cells via inhibiting DNA damage repair has been successfully used in breast and ovarian cancer using PARP inhibitors. Unfortunately, such strategies have not yet yielded results in liver cancer. Hepatocellular carcinoma (HCC), the most common type of liver cancer, is a treatment-resistant malignancy. Despite the development of guided therapies, treatment regimens for advanced HCC patients still fall short of the current need and significant problems such as cancer relapse with resistance still exist. In this paper, we targeted telomeric replication protein CTC1, which is responsible for telomere maintenance. CTC expression was analyzed using tumor and matched-tissue RNA-sequencing data from TCGA and GTEx. In HCC cell lines, q-RT-PCR and Western blotting were used to detect CTC1 expression. The knock-down of CTC1 was achieved using lentiviral plasmids. The effects of CTC1 silencing on HCC cells were analyzed by flow cytometry, MTT, spheroid and colony formation assays. CTC1 is significantly downregulated in HCC tumor samples. However, CTC1 protein levels were higher in sorafenib-resistant cell lines compared to the parental groups. CTC1 inhibition reduced cell proliferation in sorafenib-resistant HCC cell lines and diminished their spheroid and colony forming capacities. Moreover, these cells were more sensitive to single and combined drug treatment with G4 stabilizer RHPS4 and sorafenib. Our results suggest that targeting CTC1 might be a viable option for combinational therapies designed for sorafenib resistant HCC patients.
Sections du résumé
BACKGROUND
BACKGROUND
Although DNA repair mechanisms function to maintain genomic integrity, in cancer cells these mechanisms may negatively affect treatment efficiency. The strategy of targeting cancer cells via inhibiting DNA damage repair has been successfully used in breast and ovarian cancer using PARP inhibitors. Unfortunately, such strategies have not yet yielded results in liver cancer. Hepatocellular carcinoma (HCC), the most common type of liver cancer, is a treatment-resistant malignancy. Despite the development of guided therapies, treatment regimens for advanced HCC patients still fall short of the current need and significant problems such as cancer relapse with resistance still exist. In this paper, we targeted telomeric replication protein CTC1, which is responsible for telomere maintenance.
METHODS
METHODS
CTC expression was analyzed using tumor and matched-tissue RNA-sequencing data from TCGA and GTEx. In HCC cell lines, q-RT-PCR and Western blotting were used to detect CTC1 expression. The knock-down of CTC1 was achieved using lentiviral plasmids. The effects of CTC1 silencing on HCC cells were analyzed by flow cytometry, MTT, spheroid and colony formation assays.
RESULTS
RESULTS
CTC1 is significantly downregulated in HCC tumor samples. However, CTC1 protein levels were higher in sorafenib-resistant cell lines compared to the parental groups. CTC1 inhibition reduced cell proliferation in sorafenib-resistant HCC cell lines and diminished their spheroid and colony forming capacities. Moreover, these cells were more sensitive to single and combined drug treatment with G4 stabilizer RHPS4 and sorafenib.
CONCLUSION
CONCLUSIONS
Our results suggest that targeting CTC1 might be a viable option for combinational therapies designed for sorafenib resistant HCC patients.
Identifiants
pubmed: 39001931
doi: 10.1007/s11033-024-09756-3
pii: 10.1007/s11033-024-09756-3
doi:
Substances chimiques
Sorafenib
9ZOQ3TZI87
Ctc1 protein, human
0
Telomere-Binding Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
799Subventions
Organisme : Türkiye Bilimsel ve Teknolojik Araştırma Kurumu
ID : 222S568
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Balogh J, Victor D, Asham EH et al (2016) Hepatocellular carcinoma: a review. J Hepatocell Carcinoma 3:41–53
pubmed: 27785449
pmcid: 5063561
doi: 10.2147/JHC.S61146
Llovet JM, Kelley RK, Villanueva A et al (2021) Hepatocellular carcinoma. Nat Rev Dis Primer 7:1–28
doi: 10.1038/s41572-020-00240-3
Rumgay H, Arnold M, Ferlay J et al (2022) Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol 77:1598–1606
pubmed: 36208844
pmcid: 9670241
doi: 10.1016/j.jhep.2022.08.021
Siegel RL, Miller KD, Wagle NS et al (2023) Cancer statistics, 2023. CA Cancer J Clin 73:17–48
pubmed: 36633525
doi: 10.3322/caac.21763
Huang DQ, Singal AG, Kanwal F et al (2023) Hepatocellular carcinoma surveillance - utilization, barriers and the impact of changing aetiology. Nat Rev Gastroenterol Hepatol 20:797–809
pubmed: 37537332
doi: 10.1038/s41575-023-00818-8
Suresh D, Srinivas AN, Prashant A et al (2023) Therapeutic options in hepatocellular carcinoma: a comprehensive review. Clin Exp Med 23:1901–1916
pubmed: 36780119
doi: 10.1007/s10238-023-01014-3
Zhang H, Zhang W, Jiang L et al (2022) Recent advances in systemic therapy for hepatocellular carcinoma. Biomark Res 10:3
pubmed: 35000616
pmcid: 8744248
doi: 10.1186/s40364-021-00350-4
Coffman-D’Annibale K, Xie C, Hrones DM et al (2023) The current landscape of therapies for hepatocellular carcinoma. Carcinogenesis 44:537–548
pubmed: 37428789
pmcid: 10588973
doi: 10.1093/carcin/bgad052
He P, Wan H, Wan J et al Systemic therapies in hepatocellular carcinoma: Existing and emerging biomarkers for treatment response. Front Oncol; 12. Epub ahead of print 22 November 2022. https://doi.org/10.3389/fonc.2022.1015527
Cabral LKD, Tiribelli C, Sukowati CHC (2020) Sorafenib Resistance in Hepatocellular Carcinoma: the relevance of genetic heterogeneity. Cancers 12:1576
pubmed: 32549224
pmcid: 7352671
doi: 10.3390/cancers12061576
Chen J, Duda DG (2020) Overcoming sorafenib treatment-resistance in hepatocellular carcinoma: a future perspective at a time of rapidly changing treatment paradigms. EBioMedicine 52:102644
pubmed: 32014823
pmcid: 6997488
doi: 10.1016/j.ebiom.2020.102644
Firtina Karagonlar Z, Koc D, Iscan E et al (2016) Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells. Cancer Sci 107:407–416
pubmed: 26790028
pmcid: 4832867
doi: 10.1111/cas.12891
Tian X, Yan T, Liu F et al (2022) Link of sorafenib resistance with the tumor microenvironment in hepatocellular carcinoma: mechanistic insights. Front Pharmacol 13:991052
pubmed: 36071839
pmcid: 9441942
doi: 10.3389/fphar.2022.991052
Xia S, Pan Y, Liang Y et al (2020) The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma. EBioMedicine 51:102610
pubmed: 31918403
pmcid: 7000339
doi: 10.1016/j.ebiom.2019.102610
Marin JJG, Macias RIR, Monte MJ et al (2020) Molecular bases of Drug Resistance in Hepatocellular Carcinoma. Cancers 12:1663
pubmed: 32585893
pmcid: 7352164
doi: 10.3390/cancers12061663
Rinaldi L, Vetrano E, Rinaldi B et al (2021) HCC and Molecular Targeting therapies: back to the future. Biomedicines 9:1345
pubmed: 34680462
pmcid: 8533575
doi: 10.3390/biomedicines9101345
Samadaei M, Senfter D, Madlener S et al (2022) Targeting DNA repair to enhance the efficacy of sorafenib in hepatocellular carcinoma. J Cell Biochem 123:1663–1673
pubmed: 36271841
pmcid: 9828257
doi: 10.1002/jcb.30340
Yang X-D, Kong F-E, Qi L et al (2021) PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma. Mol Cancer 20:20
pubmed: 33485358
pmcid: 7824946
doi: 10.1186/s12943-021-01315-9
Wang L, Ma T, Liu W et al (2022) Pan-cancer analyses identify the CTC1-STN1-TEN1 complex as a protective factor and predictive biomarker for Immune Checkpoint Blockade in Cancer. Front Genet 13:859617
pubmed: 35368664
pmcid: 8966541
doi: 10.3389/fgene.2022.859617
Price C, Boltz KA, Chaiken MF et al (2010) Evolution of CST function in telomere maintenance. Cell Cycle 9:3177–3185
doi: 10.4161/cc.9.16.12547
Feng X, Hsu S-J, Kasbek C et al (2017) CTC1-mediated C-strand fill-in is an essential step in telomere length maintenance. Nucleic Acids Res 45:4281–4293
pubmed: 28334750
pmcid: 5416890
doi: 10.1093/nar/gkx125
Chastain M, Zhou Q, Shiva O et al (2016) Human CST facilitates genome-wide RAD51 recruitment to GC-Rich repetitive sequences in response to replication stress. Cell Rep 16:2048
pubmed: 27533181
doi: 10.1016/j.celrep.2016.08.008
Stewart JA (2018) Emerging roles of CST in maintaining genome stability and human disease. Front Biosci 23:1564–1586
doi: 10.2741/4661
Wang F, Stewart J, Price CM (2014) Human CST abundance determines recovery from diverse forms of DNA damage and replication stress. Cell Cycle 13:3488–3498
pubmed: 25483097
pmcid: 4612738
doi: 10.4161/15384101.2014.964100
Martínez P, Blasco MA (2015) Replicating through telomeres: a means to an end. Trends Biochem Sci 40:504–515
pubmed: 26188776
doi: 10.1016/j.tibs.2015.06.003
Bhattacharjee A, Wang Y, Diao J et al (2017) Dynamic DNA binding, junction recognition and G4 melting activity underlie the telomeric and genome-wide roles of human CST. Nucleic Acids Res 45:12311–12324
pubmed: 29040642
pmcid: 5716219
doi: 10.1093/nar/gkx878
Spiegel J, Adhikari S, Balasubramanian S (2020) The structure and function of DNA G-Quadruplexes. Trends Chem 2:123–136
pubmed: 32923997
pmcid: 7472594
doi: 10.1016/j.trechm.2019.07.002
Varshney D, Spiegel J, Zyner K et al (2020) The regulation and functions of DNA and RNA G-quadruplexes. Nat Rev Mol Cell Biol 21:459–474
pubmed: 32313204
pmcid: 7115845
doi: 10.1038/s41580-020-0236-x
Biffi G, Tannahill D, Miller J et al (2014) Elevated levels of G-Quadruplex formation in human stomach and Liver Cancer tissues. PLoS ONE 9:e102711
pubmed: 25033211
pmcid: 4102534
doi: 10.1371/journal.pone.0102711
Ningarhari M, Caruso S, Hirsch TZ et al (2021) Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target. J Hepatol 74:1155–1166
pubmed: 33338512
doi: 10.1016/j.jhep.2020.11.052
Chen L-Y, Majerska J, Lingner J (2013) Molecular basis of telomere syndrome caused by CTC1 mutations. Genes Dev 27:2099–2108
pubmed: 24115768
pmcid: 3850094
doi: 10.1101/gad.222893.113
Gu P, Chang S (2013) Functional characterization of human CTC1 mutations reveals novel mechanisms responsible for the pathogenesis of the telomere disease Coats plus. Aging Cell 12:1100–1109
pubmed: 23869908
doi: 10.1111/acel.12139
Surovtseva YV, Churikov D, Boltz KA et al (2009) Conserved Telomere maintenance component 1 interacts with STN1 and maintains chromosome ends in higher eukaryotes. Mol Cell 36:207–218
pubmed: 19854131
pmcid: 2768651
doi: 10.1016/j.molcel.2009.09.017
Gu P, Min J-N, Wang Y et al (2012) CTC1 deletion results in defective telomere replication, leading to catastrophic telomere loss and stem cell exhaustion: CTC1 deletion results in defective telomere replication. EMBO J 31:2309–2321
pubmed: 22531781
pmcid: 3364752
doi: 10.1038/emboj.2012.96
Boccardi V, Razdan N, Kaplunov J et al (2015) Stn1 is critical for telomere maintenance and long-term viability of somatic human cells. Aging Cell 14:372–381
pubmed: 25684230
pmcid: 4406666
doi: 10.1111/acel.12289
Stewart JA, Wang F, Chaiken MF et al (2012) Human CST promotes telomere duplex replication and general replication restart after fork stalling: CST promotes replication restart. EMBO J 31:3537–3549
pubmed: 22863775
pmcid: 3433780
doi: 10.1038/emboj.2012.215
Győrffy B, Surowiak P, Budczies J et al (2013) Online Survival Analysis Software to assess the prognostic value of biomarkers using Transcriptomic Data in Non-small-cell Lung Cancer. PLoS ONE 8:e82241
pubmed: 24367507
pmcid: 3867325
doi: 10.1371/journal.pone.0082241
Luo YM, Xia NX, Yang L et al (2014) CTC1 increases the radioresistance of human melanoma cells by inhibiting telomere shortening and apoptosis. Int J Mol Med 33:1484–1490
pubmed: 24718655
pmcid: 4055431
doi: 10.3892/ijmm.2014.1721
Lu Y, Wang S, Chi T et al (2023) DNA damage repair-related gene signature for identifying the immune status and predicting the prognosis of hepatocellular carcinoma. Sci Rep 13:18978
pubmed: 37923899
pmcid: 10624694
doi: 10.1038/s41598-023-45999-z
Lin P, Gao R, Wen R et al (2021) DNA damage repair profiles Alteration characterize a Hepatocellular Carcinoma Subtype with Unique Molecular and Clinicopathologic Features. Front Immunol 12:715460
pubmed: 34456923
pmcid: 8387599
doi: 10.3389/fimmu.2021.715460
Ackerson SM, Gable CI, Stewart JA (2020) Human CTC1 promotes TopBP1 stability and CHK1 phosphorylation in response to telomere dysfunction and global replication stress. Cell Cycle 19:3491–3507
pubmed: 33269665
pmcid: 7781613
doi: 10.1080/15384101.2020.1849979
Yadav A, Kumar B, Teknos TN et al (2011) Sorafenib enhances the Antitumor effects of Chemoradiation Treatment by Downregulating ERCC-1 and XRCC-1 DNA repair proteins. Mol Cancer Ther 10:1241–1251
pubmed: 21551262
pmcid: 3132282
doi: 10.1158/1535-7163.MCT-11-0004
Gleißner L, Kwiatkowski M, Myllynen L et al (2017) Analyzing the influence of kinase inhibitors on DNA repair by differential proteomics of chromatin-interacting proteins and nuclear phospho-proteins. Oncotarget 8:110983–110993
pubmed: 29340031
pmcid: 5762299
doi: 10.18632/oncotarget.22424
Caruso S, Calatayud AL, Pilet J, La Bella T, Rekik S, Imbeaud S, Letouzé E, Meunier L, Bayard Q, Rohr-Udilova N, Péneau C, Grasl-Kraupp B, de Koning L, Ouine B, Bioulac-Sage P, Couchy G, Calderaro J, Nault JC, Zucman-Rossi J, Rebouissou S (2019) Analysis of Liver Cancer Cell lines identifies agents with likely efficacy against hepatocellular carcinoma and markers of response. Gastroenterology 157(3):760–776
pubmed: 31063779
doi: 10.1053/j.gastro.2019.05.001
Ayvaz I, Sunay D, Sariyar E et al (2021) Three-Dimensional Cell Culture models of Hepatocellular Carcinoma — a review. J Gastrointest Cancer 52:1294–1308
pubmed: 34927218
doi: 10.1007/s12029-021-00772-1
Kim D-S, Camacho CV, Kraus WL (2021) Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance. Exp Mol Med 53:42–51
pubmed: 33487630
pmcid: 8080675
doi: 10.1038/s12276-021-00557-3
Prasad CB, Prasad SB, Yadav SS et al (2017) Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property. Sci Rep 7:12876
pubmed: 28993682
pmcid: 5634505
doi: 10.1038/s41598-017-13232-3
Qin C, Ji Z, Zhai E et al (2022) PARP inhibitor olaparib enhances the efficacy of radiotherapy on XRCC2-deficient colorectal cancer cells. Cell Death Dis 13:505
pubmed: 35643812
pmcid: 9148313
doi: 10.1038/s41419-022-04967-7
Barazas M, Annunziato S, Pettitt SJ et al (2018) The CST Complex mediates End Protection at double-strand breaks and promotes PARP inhibitor sensitivity in BRCA1-Deficient cells. Cell Rep 23:2107–2118
pubmed: 29768208
pmcid: 5972230
doi: 10.1016/j.celrep.2018.04.046
Phatak P, Cookson JC, Dai F et al (2007) Telomere uncapping by the G-quadruplex ligand RHPS4 inhibits clonogenic tumour cell growth in vitro and in vivo consistent with a cancer stem cell targeting mechanism. Br J Cancer 96:1223–1233
pubmed: 17406367
pmcid: 2360152
doi: 10.1038/sj.bjc.6603691
Kim B, Yun W, Lee S-T et al (2020) Prevalence and clinical implications of germline predisposition gene mutations in patients with acute myeloid leukemia. Sci Rep 10:14297
pubmed: 32868804
pmcid: 7459095
doi: 10.1038/s41598-020-71386-z
Liu L, Luo H, Sheng Y et al (2023) A novel mutation of CTC1 leads to telomere shortening in a Chinese family with interstitial lung disease. Hereditas 160:37
pubmed: 37978541
pmcid: 10656953
doi: 10.1186/s41065-023-00299-4
Doubkova M, Vrzalová Z, Štefániková M et al Germline variant of CTC1 gene in a patient with pulmonary fibrosis and myelodysplastic syndrome. Multidiscip Respir Med; 18. Epub ahead of print 5 June 2023. https://doi.org/10.4081/mrm.2023.909
Dos Santos GA, Viana NI, Pimenta R et al (2022) Pan-cancer analysis reveals that CTC1-STN1-TEN1 (CST) complex may have a key position in oncology. Cancer Genet 262–263:80–90
pubmed: 35134616
doi: 10.1016/j.cancergen.2022.01.006
Olson CL, Barbour AT, Wieser TA et al (2023) RPA engages telomeric G-quadruplexes more effectively than CST. Nucleic Acids Res 51:5073–5086
pubmed: 37140062
pmcid: 10250233
doi: 10.1093/nar/gkad315
Jiang D, Ma X, Zhang X et al (2023) New techniques: a roadmap for the development of HCC immunotherapy. Front Immunol 14:1121162
pubmed: 37426674
pmcid: 10323423
doi: 10.3389/fimmu.2023.1121162
Pelizzaro F, Farinati F, Trevisani F (2023) Immune checkpoint inhibitors in Hepatocellular Carcinoma: current strategies and biomarkers Predicting Response and/or resistance. Biomedicines 11:1020
pubmed: 37189643
pmcid: 10135644
doi: 10.3390/biomedicines11041020